We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03132324
Recruitment Status : Terminated (This study is terminated due to a business decision not to pursue INCB059782 in Sickle Cell Disease indication.)
First Posted : April 27, 2017
Last Update Posted : October 28, 2019
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study was to evaluate the safety and tolerability, and the pharmacokinetic and biologic activity of INCB059872 in participants with sickle cell disease.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: INCB059872 Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
Actual Study Start Date : April 20, 2017
Actual Primary Completion Date : October 3, 2018
Actual Study Completion Date : October 3, 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: INCB059872 0.5 mg
INCB059872 0.5 mg tablet administered orally every other day (QOD) for 28 days on an empty stomach. If dose was well tolerated, once daily (QD) administration was evaluated independently and in parallel with QOD administration.
 Drug: INCB059872
INCB059872 tablets
Experimental: INCB059872 1 mg
INCB059872 1 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
 Drug: INCB059872
INCB059872 tablets
Experimental: INCB059872 2 mg
INCB059872 2 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
 Drug: INCB059872
INCB059872 tablets


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety and tolerability of INCB059872 assessed by monitoring frequency, duration, and severity of adverse events [ Time Frame: Screening through 35 days after end of treatment, up to approximately 3 months per participant. ]
    An adverse event is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.

  2. Change in fetal hemoglobin (HbF) from baseline [ Time Frame: Baseline through 2 weeks after end of treatment, up to approximately 2.5 months per participant. ]
    Pharmacodynamic activity assessed by measuring changes of HbF from baseline and their correlation to INCB059872 treatment. The HbF (F cells) in human whole blood will be characterized using flow cytometry.


Secondary Outcome Measures :
  1. Cmax of INCB059872 [ Time Frame: Baseline to Day 28. ]
    Defined as maximum observed plasma concentration.

  2. AUC0-t of INCB059872 [ Time Frame: Baseline to Day 28. ]
    Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of SCD (sickle cell SS) confirmed through hemoglobin electrophoresis.
  • Must be red blood cell (RBC) transfusion-independent (not currently on regularly scheduled transfusions) for ≥ 3 months from the time of first dose of study drug.
  • No RBC transfusion within 30 days of first dose of study drug.

  • Hydroxyurea (HU) refractory

    -Must not have received HU therapy during the 3 months before receiving study drug.

  • Creatinine clearance ≥ 60 mL/min based on the institutional formula.
  • Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

  • Any unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic toxicities not expected to resolve.
  • Pregnant or nursing women or participants expecting to conceive or father children within the projected duration of the study, starting with screening visit through completion of safety follow-up.
  • Received an investigational study drug within 28 days or 5 half-lives (whichever is longer) before receiving the first dose of study drug (requirement may be waived with medical monitor approval).
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
  • Prior receipt of LSD1 inhibitor therapy for any indication.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03132324


Locations
Layout table for location information
United States, Florida
Acevedo Clinical Research Associates
Miami, Florida, United States, 33142
Advanced Pharma
Miami, Florida, United States, 33147
Vita Health and Medical Center
Tamarac, Florida, United States, 33319
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60607
United States, Massachusetts
Boston University
Boston, Massachusetts, United States, 02215
United States, Virginia
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
United States, Wisconsin
Blood Centers of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Incyte Corporation
Investigators
Layout table for investigator information
Study Director: Fitzroy Dawkins, MD Incyte Corporation
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT03132324    
Other Study ID Numbers: INCB 59872-102
First Posted: April 27, 2017    Key Record Dates
Last Update Posted: October 28, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
Sickle cell disease (SCD)
sickle cell SS
lysine demethylase 1 (LSD1) inhibition
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
 Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn